Iodixanol 320 results in better renal tolerance and radiodensity than do gadolinium-based contrast media: Arteriography in ischemic porcine kidneys

Radiology

Volumn 247, Issue 1, 2008, Pages 88-97

  Elmståhl, Barbara ^a   Nyman, Ulf ^b   Leander, Peter ^a   Golman, Klaes ^c   Chai, Chun Ming ^a   Grant, Derek ^d   Doughty, Richard ^d   Pehrson, Rikard ^c   Björk, Jonas ^a   Almén, Torsten ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Lasarettet Trelleborg ^*  (Sweden)

^c BIACORE AB   (Sweden)

^d GE Healthcare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBUTROL; GADODIAMIDE; IODIXANOL; IOPROMIDE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM; GADOLINIUM PENTETATE; IODOBENZOIC ACID DERIVATIVE; ORGANOMETALLIC COMPOUND;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG TOLERANCE; GLOMERULUS FILTRATION RATE; KIDNEY ARTERIOGRAPHY; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY NECROSIS; KIDNEY PARENCHYMA; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SWINE; ANIMAL; DRUG EFFECT; ISCHEMIA; KIDNEY; NECROSIS; PATHOLOGY; RADIOGRAPHY; RENAL ARTERY; VASCULARIZATION;

ANIMALS; CONTRAST MEDIA; GADOLINIUM; GADOLINIUM DTPA; ISCHEMIA; KIDNEY; MALE; NECROSIS; ORGANOMETALLIC COMPOUNDS; RENAL ARTERY; SUS SCROFA; TRIIODOBENZOIC ACIDS;

EID: 42449138730     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2471070420     Document Type: Article

References (47)

1. Kaufman JA, Geller SC, Waltman AC. Renal insufficiency: gadopentetate dimeglumine as a radiographic contrast agent during peripheral vascular interventional procedures. Radiology 1996;198(2):579-581.
2. Spinosa DJ, Matsumoto AH, Hagspiel KD, Angle JF, Hartwell GD. Gadolinium-based contrast agents in angiography and interventional radiology. AJR Am J Roentgenol 1999;173(5):1403-1409.
3. Strunk HM, Schild H. Actual clinical use of gadolinium-chelates for non-MRI applications. Eur Radiol 2004;14(6):1055-1062.
4. Ailawadi G, Stanley JC, Williams DM, Dimick JB, Henke PK, Upchurch GR Jr. Gadolinium as a nonnephrotoxic contrast agent for catheter-based arteriographic evaluation of renal arteries in patients with azotemia. J Vasc Surg 2003;37(2):346-352.
5. Trani C, Burzotta F, Biondi-Zoccai GG, et al. Use of a novel high-osmolar gadolinium chelate, gadobutrol, for percutaneous renal artery stenting in two patients with chronic renal failure. Int J Cardiol 2005;102(2):361-362.
6. Erley CM, Bader BD, Berger ED, et al. Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients. Nephrol Dial Transplant 2004;19(10):2526-2531.
7. Remy-Jardin M, Bahepar J, Lafitte JJ, et al. Multi-detector row CT angiography of pulmonary circulation with gadolinium-based contrast agents: prospective evaluation in 60 patients. Radiology 2006;238(3):1022-1035.
8. Barcin C, Kursaklioglu H, Iyisoy A, Kose S, Tore HF, Isik E. Safety of gadodiamide mixed with a small quantity of iohexol in patients with impaired renal function undergoing coronary angiography. Heart Vessels 2006;21(3):141-145.
9. Briguori C, Colombo A, Airoldi F, et al. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheter Cardiovasc Interv 2006;67(2):175-180.
10. Nyman U, Elmståhl B, Leander P, Nilsson M, Golman K, Almén T. Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia? Radiology 2002;223(2):311-318.
11. Dawson P, Cosgrove D, Grainger R, eds. Textbook of contrast media. Oxford, England: Isis Medical Media, 1999.
12. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993;188(1):171-178.
13. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial-the Iohexol Cooperative Study. Kidney Int 1995;47(1):254-261.
14. Andrew E. Assessment of safety of contrast media. In: Dawson P, Cosgrove D, Grainger R, eds. Textbook of contrast media. Oxford, England: Isis Medical Media, 1999; 47-59.
15. Weinmann HJ. Gadolinium chelates: physicochemical properties, formulation, and toxicology. In: Dawson P, Cosgrove DO, Grainger RG, eds. Textbook of contrast media. Oxford, England: Isis Medical Media, 1999; 297-321.
16. Bussi S, Morisetti A. Margins of safety of intravascular contrast media: body weight, surface area, or toxicokinetic approach? Arh Hig Rada Toksikol 2005;56(2):157-160.
17. Elmståhl B, Nyman U, Leander P, Chai CM, Frennby B, Almén T. Gadolinium contrast media are more nephrotoxic than a low osmolar iodine medium employing doses with equal x-ray attenuation in renal arteriography: an experimental study in pigs. Acad Radiol 2004;11(11):1219-1228.
18. Elmståhl B, Nyman U, Leander P, et al. Gadolinium contrast media are more nephrotoxic than iodine media: the importance of osmolality in direct renal artery injections. Eur Radiol 2006;16(12):2712-2720.
19. Elmståhl B. Are gadolinium contrast media really less nephrotoxic than iodine agents in radiographic examinations? a comparison in relation to their ability to attenuate x-rays in a pig model [doctoral dissertation]. Malmö, Sweden: Lund University, 2006.
20. Heinrich MC, Kuhlmann MK, Kohlbacher S, et al. Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study. Radiology 2007;242(2):425-434.
21. Almén T, Frennby B, Sterner G. Trends in contrast media: determination of glomerular filtration rate with contrast media. In: Thomsen HS, Muller RN, Mattrey RF, eds. Medical radiology: diagnostic imaging and radiation oncology. Berlin, Germany: Springer-Verlag, 1999; 81-94.
22. Schmitz SA, Wagner S, Schuhmann-Giampieri G, Wolf KJ. Evaluation of gadobutrol in a rabbit model as a new lanthanide contrast agent for computed tomography. Invest Radiol 1995;30(11):644-649.
23. Choyke PL, Austin HA, Frank JA, et al. Hydrated clearance of gadolinium-DTPA as measurement of glomerular filtration rate. Kidney Int 1992;41(6):1595-1598.
24. Greenblatt DJ, Shader RI. Pharmacokinetics in clinical practice. Philadelphia, Pa: Saunders, 1985.
25. Grönberg T, Sjöberg S, Almén T, Golman K, Mattson S. Noninvasive estimation of kidney function by x-ray fluorescence analysis: elimination rate and clearance of contrast media injected for urography in man. Invest Radiol 1983;18(5):445-452.
26. Lorusso V, Arbughi T, Tirone P, de Haen C. Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance). J Comput Assist Tomogr 1999;23(suppl 1):S181-S194.
27. Hollander M, Wolfe DA. Nonparametric statistical methods. New York, NY: Wiley, 1999.
28. Van Wagoner M, Worah D. Gadodiamide injection: first human experience with the nonionic magnetic resonance imaging enhancement agent. Invest Radiol 1993;28(suppl 1):S44-S48.
29. Hackstein N, Langheinrich AC, Rau WS. Iopromide one-sample clearance as a measure of glomerular filtration rate. Clin Physiol Funct Imaging 2002;22(2):99-107.
30. Love L, Johnson MS, Bresler ME, Nelson JE, Olson MC, Flisak ME. The persistent computed tomography nephrogram: its significance in the diagnosis of contrast-associated nephrotoxicity. Br J Radiol 1994;67(802):951-957.
31. Tumlin J, Stacul F, Adam A, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006;98(6A):59K-77K.
32. Törnquist C, Almén T, Golman K, Holtås S. Renal function following nephroangiography with diatrizoate: effects of saline, mannitol, and diatrizoate on renal blood flow, glomerular permeability and filtration rate and diuresis in dogs. Acta Radiol Diagn (Stockh) 1984;25(4):343-350.
33. Heyman SN, Reichman J, Brezis M. Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. Invest Radiol 1999;34(11):685-691.
34. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005;68(1):14-22.
35. Aspelin P. Effect of ionic and non-ionic contrast media on red cell deformability in vitro. Acta Radiol Diagn (Stockh) 1979;20(1):1-12.
36. Almén T, Bergentz SE, Törnquist C, Öystese B. Selective nephroangiography in the dog causing renal platelet aggregation and irregular nephrographic phase. Acta Radiol Diagn (Stockh) 1985;26(5):627-634.
37. Heinrich MC, Kuhlmann MK, Grgic A, Heckmann M, Kramann B, Uder M. Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology 2005;235(3):843- 849.
38. Berg KJ, Jakobsen JA. Renal tolerance of nonionic dimers in humans: how relevant are experiments in rats? Invest Radiol 1997;32(6):368-370.
39. Idée JM, Bonnemain B. Reliability of experimental models of iodinated contrast media-induced acute renal failure: from methodological considerations to pathophysiology. Invest Radiol 1996;31(4):230-241.
40. Sharafuddin MJ, Stolpen AH, Dixon BS, Andresen KJ, Sun S, Lawton WJ. Value of MR angiography before percutaneous transluminal renal artery angioplasty and stent placement. J Vasc Interv Radiol 2002;13(9 pt 1):901-908.
41. Mannebach PC, Dieter RS, Marks DS. Use of gadolinium-based angiography for renal artery stenting in a patient with renal insufficiency: a case report. Angiology 2006;57(4):526-529.
42. Dieu V, Joffre F, Krause D, et al. A comparison of the efficacy and safety of ioxaglate and iobitridol in renal angioplasty. Cardiovasc Intervent Radiol 2000;23(2):91-96.
43. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 suppl 1):S1-S266.
44. Frennby B, Sterner G. Contrast media as markers of GFR. Eur Radiol 2002;12(2):475-484.
45. Vogler H, Platzek J, Schuhmann-Giampieri G, et al. Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging. Eur J Radiol 1995;21(1):1-10.
46. Svaland MG, Haider T, Langseth-Marique K, Andrew E, Hals PA. Human pharmacokinetics of iodixanol. Invest Radiol 1992;27(2):130-133.
47. Heglund IF, Michelet AA, Blazak WF, Furuhama K, Holtz E. Preclinical pharmacokinetics and general toxicology of iodixanol. Acta Radiol Suppl 1995;399:69-82.